Company profile for Perception Neuroscience

NEW Drugs in Dev: 1
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Perception Neuroscience’s lead development product is the NMDA antagonist arketamine (PCN-101), a single isomer of ketamine. Arketamine belongs to a new generation of glutamate receptor modulators with the suggested potential for rapid acting antidepressant (RAAD) activity. Most of the currently FDA-approved antidepressant therapies often take weeks to achieve maximal effectiveness. Perception Neuroscience was founded on the...
Perception Neuroscience’s lead development product is the NMDA antagonist arketamine (PCN-101), a single isomer of ketamine. Arketamine belongs to a new generation of glutamate receptor modulators with the suggested potential for rapid acting antidepressant (RAAD) activity. Most of the currently FDA-approved antidepressant therapies often take weeks to achieve maximal effectiveness. Perception Neuroscience was founded on the basis of evidence from animal models of depression as well as safety reports from academic studies in healthy volunteers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
180 Varick Street, Suite 637 New York, NY 10014
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2022/10/25/2540677/0/en/atai-Life-Sciences-Company-Perception-Neuroscience-Completes-Enrollment-for-Phase-2a-Clinical-Trial-of-PCN-101-R-Ketamine-for-Treatment-Resistant-Depression.html

GLOBENEWSWIRE
25 Oct 2022

https://www.globenewswire.com/news-release/2021/09/14/2296596/0/en/Perception-Neuroscience-initiates-Phase-2a-study-of-PCN-101-R-ketamine-for-treatment-resistant-depression.html

GLOBENEWSWIRE
14 Sep 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty